表观遗传对基因引发的胸主动脉瘤的影响。
Epigenetic influences on genetically triggered thoracic aortic aneurysm.
作者信息
Portelli Stefanie S, Robertson Elizabeth N, Malecki Cassandra, Liddy Kiersten A, Hambly Brett D, Jeremy Richmond W
机构信息
Discipline of Pathology and Bosch Institute, The University of Sydney, Sydney, NSW, 2006, Australia.
Cardiology Department, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
出版信息
Biophys Rev. 2018 Oct;10(5):1241-1256. doi: 10.1007/s12551-018-0460-1. Epub 2018 Sep 28.
Abstract
Genetically triggered thoracic aortic aneurysms (TAAs) account for 30% of all TAAs and can result in early morbidity and mortality in affected individuals. Epigenetic factors are now recognised to influence the phenotype of many genetically triggered conditions and have become an area of interest because of the potential for therapeutic manipulation. Major epigenetic modulators include DNA methylation, histone modification and non-coding RNA. This review examines epigenetic modulators that have been significantly associated with genetically triggered TAAs and their potential utility for translation to clinical practice.
摘要
基因引发的胸主动脉瘤（TAA）占所有TAA的30%，可导致受影响个体出现早期发病和死亡。现在人们认识到表观遗传因素会影响许多基因引发疾病的表型，并且由于其在治疗操作方面的潜力而成为一个研究热点。主要的表观遗传调节因子包括DNA甲基化、组蛋白修饰和非编码RNA。本综述探讨了与基因引发的TAA显著相关的表观遗传调节因子及其转化为临床实践的潜在用途。
相似文献
1
Epigenetic influences on genetically triggered thoracic aortic aneurysm.表观遗传对基因引发的胸主动脉瘤的影响。
Biophys Rev. 2018 Oct;10(5):1241-1256. doi: 10.1007/s12551-018-0460-1. Epub 2018 Sep 28.
2
Surgical treatment of patients enrolled in the national registry of genetically triggered thoracic aortic conditions.纳入国家遗传性胸主动脉疾病登记系统的患者的外科治疗。
Ann Thorac Surg. 2009 Sep;88(3):781-7; discussion 787-8. doi: 10.1016/j.athoracsur.2009.04.034.
3
Rationale and design of the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC).国家遗传性触发胸主动脉瘤和心血管疾病注册库（GenTAC）的原理与设计
Am Heart J. 2009 Feb;157(2):319-26. doi: 10.1016/j.ahj.2008.10.005. Epub 2008 Dec 17.
4
Oxidative stress in genetically triggered thoracic aortic aneurysm: role in pathogenesis and therapeutic opportunities.遗传性胸主动脉瘤中的氧化应激：在发病机制和治疗机会中的作用。
Redox Rep. 2021 Dec;26(1):45-52. doi: 10.1080/13510002.2021.1899473.
5
Endovascular repair of descending thoracic aortic aneurysm: an evidence-based analysis.降主动脉瘤的血管腔内修复：一项基于证据的分析。
Ont Health Technol Assess Ser. 2005;5(18):1-59. Epub 2005 Nov 1.
6
Prevalence of Thoracic Aortic Aneurysms in Patients with Degenerative Abdominal Aortic Aneurysms: Results from the Prospective ACTA Study.胸主动脉瘤在退行性腹主动脉瘤患者中的发生率：前瞻性 ACTA 研究结果。
Eur J Vasc Endovasc Surg. 2021 Jun;61(6):930-937. doi: 10.1016/j.ejvs.2021.03.004. Epub 2021 Apr 20.
7
A biologic basis for asymmetric growth in descending thoracic aortic aneurysms: a role for matrix metalloproteinase 9 and 2.降主动脉瘤不对称生长的生物学基础：基质金属蛋白酶9和2的作用
J Vasc Surg. 2006 Feb;43(2):342-8. doi: 10.1016/j.jvs.2005.10.013.
8
Familial thoracic aortic aneurysms and dissections--incidence, modes of inheritance, and phenotypic patterns.家族性胸主动脉瘤和夹层——发病率、遗传模式及表型特征
Ann Thorac Surg. 2006 Oct;82(4):1400-5. doi: 10.1016/j.athoracsur.2006.04.098.
9
Epigenetic regulation of TGF-β1 signalling in dilative aortopathy of the thoracic ascending aorta.胸主动脉扩张性病变中转化生长因子-β1信号通路的表观遗传调控
Clin Sci (Lond). 2016 Aug 1;130(16):1389-405. doi: 10.1042/CS20160222.
10
In search of a new therapeutic target for the treatment of genetically triggered thoracic aortic aneurysms and cardiovascular conditions: insights from human and animal lathyrism.寻找治疗遗传性胸主动脉瘤和心血管疾病的新治疗靶点：来自人类和动物山黧豆中毒的见解
Interact Cardiovasc Thorac Surg. 2010 Sep;11(3):271-6. doi: 10.1510/icvts.2010.239681. Epub 2010 Jun 14.
引用本文的文献
1
Epigenetic Biomarkers in Thoracic Aortic Aneurysm, Dissection, and Bicuspid Aortopathy: A Comprehensive Review.胸主动脉瘤、夹层和二叶式主动脉病变中的表观遗传生物标志物：综述
Biomolecules. 2025 Apr 11;15(4):568. doi: 10.3390/biom15040568.
2
The key role of miRNA in syndromic and sporadic forms of ascending aortic aneurysms as biomarkers and targets of novel therapeutic strategies.微小RNA（miRNA）在综合征型和散发性升主动脉瘤中作为生物标志物及新型治疗策略靶点的关键作用。
Front Genet. 2024 Feb 21;15:1365711. doi: 10.3389/fgene.2024.1365711. eCollection 2024.
3
Evaluation of microRNA Expression Features in Patients with Various Types of Arterial Damage: Thoracic Aortic Aneurysm and Coronary Atherosclerosis.不同类型动脉损伤患者的微小RNA表达特征评估：胸主动脉瘤和冠状动脉粥样硬化
J Pers Med. 2023 Jul 20;13(7):1161. doi: 10.3390/jpm13071161.
4
2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.2022 ACC/AHA 血管疾病诊断与管理指南：美国心脏协会/美国心脏病学会联合委员会临床实践指南的报告。
J Thorac Cardiovasc Surg. 2023 Nov;166(5):e182-e331. doi: 10.1016/j.jtcvs.2023.04.023. Epub 2023 Jun 28.
5
Molecular Mechanisms in Genetic Aortopathy-Signaling Pathways and Potential Interventions.遗传性主动脉病的分子机制-信号通路与潜在干预措施。
Int J Mol Sci. 2023 Jan 16;24(2):1795. doi: 10.3390/ijms24021795.
6
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.2022 ACC/AHA 血管疾病诊断与管理指南：美国心脏协会/美国心脏病学会联合临床实践指南委员会的报告。
J Am Coll Cardiol. 2022 Dec 13;80(24):e223-e393. doi: 10.1016/j.jacc.2022.08.004. Epub 2022 Nov 2.
7
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.2022 ACC/AHA 血管疾病诊断与管理指南：美国心脏协会/美国心脏病学会联合临床实践指南委员会的报告。
Circulation. 2022 Dec 13;146(24):e334-e482. doi: 10.1161/CIR.0000000000001106. Epub 2022 Nov 2.
8
An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome.马凡氏综合征的研究性和实验性药物治疗策略概述
J Exp Pharmacol. 2021 Aug 11;13:755-779. doi: 10.2147/JEP.S265271. eCollection 2021.
9
Rare Causes of Arterial Hypertension and Thoracic Aortic Aneurysms-A Case-Based Review.动脉高血压和胸主动脉瘤的罕见病因——基于病例的综述
Diagnostics (Basel). 2021 Mar 5;11(3):446. doi: 10.3390/diagnostics11030446.
10
The RNA-binding fragile-X mental retardation protein and its role beyond the brain.RNA结合脆性X智力低下蛋白及其在脑外的作用。
Biophys Rev. 2020 Aug;12(4):903-916. doi: 10.1007/s12551-020-00730-4. Epub 2020 Jul 11.
本文引用的文献
1
Novel Approaches for BAV Aortopathy Prediction-Is There a Need for Cohort Studies and Biomarkers?新型方法预测 BA V 主动脉病——是否需要队列研究和生物标志物？
Biomolecules. 2018 Jul 19;8(3):58. doi: 10.3390/biom8030058.
2
Angiotensin, transforming growth factor β and aortic dilatation in Marfan syndrome: Of mice and humans.马凡综合征中的血管紧张素、转化生长因子β与主动脉扩张：小鼠与人类研究
Int J Cardiol Heart Vasc. 2018 Mar 12;18:71-80. doi: 10.1016/j.ijcha.2018.02.009. eCollection 2018 Mar.
3
Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities.血管疾病的表观遗传调控：评估证据与探索机遇
Vascul Pharmacol. 2018 Mar 14. doi: 10.1016/j.vph.2018.02.009.
4
Deregulated microRNA and mRNA expression profiles in the peripheral blood of patients with Marfan syndrome.马凡综合征患者外周血中失调的 microRNA 和 mRNA 表达谱。
J Transl Med. 2018 Mar 12;16(1):60. doi: 10.1186/s12967-018-1429-3.
5
Dual-Targeted Theranostic Delivery of miRs Arrests Abdominal Aortic Aneurysm Development.双重靶向治疗 miR 的递送来阻止腹主动脉瘤的发展。
Mol Ther. 2018 Apr 4;26(4):1056-1065. doi: 10.1016/j.ymthe.2018.02.010. Epub 2018 Feb 16.
6
An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm.一种HDAC9-MALAT1-BRG1复合物介导胸主动脉瘤中的平滑肌功能障碍。
Nat Commun. 2018 Mar 8;9(1):1009. doi: 10.1038/s41467-018-03394-7.
7
Evaluation of microribonucleic acids as potential biomarkers in the bicuspid aortic valve-associated aortopathy.评估微小核糖核酸作为二叶式主动脉瓣相关主动脉病变潜在生物标志物的作用。
Interact Cardiovasc Thorac Surg. 2018 Jul 1;27(1):60-66. doi: 10.1093/icvts/ivy033.
8
Expert consensus recommendations on the cardiogenetic care for patients with thoracic aortic disease and their first-degree relatives.胸主动脉疾病患者及其一级亲属的心脏遗传学护理专家共识建议。
Int J Cardiol. 2018 May 1;258:243-248. doi: 10.1016/j.ijcard.2018.01.145. Epub 2018 Feb 7.
9
LncRNAs in vascular biology and disease.长链非编码 RNA 与血管生物学和疾病
Vascul Pharmacol. 2019 Mar;114:145-156. doi: 10.1016/j.vph.2018.01.003. Epub 2018 Feb 6.
10
A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3.LDS 相关基因 TGFB2/3 和 SMAD2/3 的突变更新。
Hum Mutat. 2018 May;39(5):621-634. doi: 10.1002/humu.23407. Epub 2018 Mar 6.
Zotero 插件